Literature DB >> 22211959

Giant basal cell carcinoma of the skin: literature review and personal experience.

G Zoccali1, R Pajand, P Papa, G Orsini, N Lomartire, M Giuliani.   

Abstract

As the most common form of skin cancer, basal cell carcinoma (BCC) is typified by locally infiltrative growth and a very low risk of metastasis. On occasion, however, this otherwise indolent neoplasm may behave aggressively, demonstrating deep tissue invasion and a high rate of postsurgical recurrence. The pathogenesis and determinants of such tenacious growth are not completely understood. Only 1% of all BCC's achieve the status of 'giant', as defined in 1988 by the American Joint Committee on Cancer. In this article, the authors provide a comprehensive review of the scientific literature on giant basal cell carcinoma (GBCC) of the skin and report their experience with this rare tumour subtype.
© 2011 The Authors. Journal of the European Academy of Dermatology and Venereology © 2011 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2011        PMID: 22211959     DOI: 10.1111/j.1468-3083.2011.04427.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  12 in total

1.  Giant Basal Cell Carcinomas Express Neuroactive Mediators and Show a High Growth Rate: A Case-Control Study and Meta-Analysis of Etiopathogenic and Prognostic Factors.

Authors:  Mohammad-Ali Yazdani Abyaneh; Peter Engel; Andrzej Slominski; Bruce Ragsdale; Richard Agag; Daniel Cramer; J Andrew Carlson
Journal:  Am J Dermatopathol       Date:  2017-03       Impact factor: 1.533

2.  Systemic therapy for inoperable and metastatic basal cell cancer.

Authors:  Leslie A Fecher
Journal:  Curr Treat Options Oncol       Date:  2013-06

3.  Giant epithelial malignancies (Basal cell carcinoma, squamous cell carcinoma): a series of 20 tumors from a single center.

Authors:  Uwe Wollina; Yousef Bayyoud; Claudia Krönert; Andreas Nowak
Journal:  J Cutan Aesthet Surg       Date:  2012-01

4.  Metastatic giant basal cell carcinoma: a case report.

Authors:  Khadija Bellahammou; Asmaa Lakhdissi; Othman Akkar; Fadoua Rais; Benhmidou Naoual; Ibrahim Elghissassi; Hind M'rabti; Hassan Errihani
Journal:  Pan Afr Med J       Date:  2016-06-22

5.  Metastatic Basal Cell Carcinoma: Case Report and Review of the Literature.

Authors:  José-Francisco Millán-Cayetano; Nuria Blázquez-Sánchez; Inés Fernández-Canedo; Juan Bosco Repiso-Jiménez; Rafael Fúnez-Liébana; María Dolores Bautista; Magdalena de Troya-Martin
Journal:  Indian J Dermatol       Date:  2020 Jan-Feb       Impact factor: 1.494

6.  Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective.

Authors:  J T Lear; C Corner; P Dziewulski; K Fife; G L Ross; S Varma; C A Harwood
Journal:  Br J Cancer       Date:  2014-09-11       Impact factor: 7.640

Review 7.  Advanced basal cell carcinoma, the hedgehog pathway, and treatment options - role of smoothened inhibitors.

Authors:  Leslie A Fecher; William H Sharfman
Journal:  Biologics       Date:  2015-11-06

Review 8.  Gene Expression and Proteome Analysis as Sources of Biomarkers in Basal Cell Carcinoma.

Authors:  Mihai Lupu; Constantin Caruntu; Mihaela Adriana Ghita; Vlad Voiculescu; Suzana Voiculescu; Adrian E Rosca; Ana Caruntu; Liliana Moraru; Iris Maria Popa; Bogdan Calenic; Maria Greabu; Daniela Elena Costea
Journal:  Dis Markers       Date:  2016-08-08       Impact factor: 3.434

9.  A Rare Case of Giant Basal Cell Carcinoma of the Abdominal Wall: Excision and Immediate Reconstruction with a Pedicled Deep Inferior Epigastric Artery Perforator (DIEP) Flap.

Authors:  Sara Di Lorenzo; Giovanni Zabbia; Bartolo Corradino; Massimiliano Tripoli; Roberto Pirrello; Adriana Cordova
Journal:  Am J Case Rep       Date:  2017-12-04

10.  Conventional Versus Giant Basal Cell Carcinoma, a Review of 57 Cases: Histologic Differences Contributing to Excessive Growth.

Authors:  J Chase Purnell; Jerad M Gardner; J Ahmad Brown; Sara C Shalin
Journal:  Indian J Dermatol       Date:  2018 Mar-Apr       Impact factor: 1.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.